Released: 4/2/2020 10:32:48 AM
Buffalo General Medical Center and Millard Fillmore Suburban Hospital are currently participating in an FDA-approved clinical trial designed to study the effects of an arthritis medication, sarilumab, used to suppress a potent inflammatory cytokine that is thought to drive some of the more serious respiratory complications of COVID-19 infection. A small study conducted in China earlier this year yielded some positive results, and we hope is to start enrolling our first patients this week. Read the full story here.
The FDA also recently announced hospitals could begin convalescent plasma trials as a way to treat critically-ill COVID-19 patients. Plasma taken from a convalescent – someone who has recovered from the illness – contains antibodies that can fight COVID-19. Plasma containing the antibodies is harvested from the blood of someone in recovery and injected into a patient who is still suffering. This prompts the body to create antibodies and fight the virus. The treatment showed some promise fighting SARS, Ebola and influenza H1N1 in recent years. Researchers and physicians at University at Buffalo and Kaleida Health have begun working on a proposal to begin the process for patients at Buffalo General Medical Center and Millard Fillmore Suburban Hospital.
In a joint effort, Kaleida Health and Erie County Medical Center have requested the use of a promising antiviral medication, Remdesivir, initially developed to fight Ebola through Gilead Sciences, Inc.’s expanded access program. If approved, Kaleida Health will be able to provide this medication to critically- ill adult patients at both Buffalo General Medical Center and Millard Fillmore Suburban Hospital. The mediation is currently only available to us through compassionate use in children and pregnant patients.